National Institute Of Cardiovascular Diseases, Pakistan

This trial investigates whether vericiguat, added to standard treatment, can improve quality of life and reduce hospitalizations in adults with heart failure and reduced ejection fraction. Participants receive either vericiguat or a placebo for six months, and their health status…